Syringe service program-based telemedicine linkage to opioid use disorder treatment: protocol for the STAMINA randomized control trial

Dennis P Watson, James A Swartz, Lisa Robison-Taylor, Mary Ellen Mackesy-Amiti, Kim Erwin, Nicole Gastala, Antonio D Jimenez, Monte D Staton, Sarah Messmer, Dennis P Watson, James A Swartz, Lisa Robison-Taylor, Mary Ellen Mackesy-Amiti, Kim Erwin, Nicole Gastala, Antonio D Jimenez, Monte D Staton, Sarah Messmer

Abstract

Background: A key strategy for mitigating the current opioid epidemic is expanded access to medications for treating opioid use disorder (MOUD). However, interventions developed to expand MOUD access have limited ability to engage opioid users at higher levels of overdose risk, such as those who inject opioids. This paper describes the study protocol for testing STAMINA (Syringe Service Telemedicine Access for Medication-assisted Intervention through NAvigation), an intervention that engages high-risk opioid users at community-based syringe service programs (SSP) and quickly links them to MOUD using a telemedicine platform.

Methods: This randomized control trial will be conducted at three SSP sites in Chicago. All participants will complete an initial assessment with a provider from a Federally Qualified Health Center who can prescribe or refer MOUD services as appropriate. The control arm will receive standard referral to treatment and the intervention arm will receive immediate telemedicine linkage to the provider and (depending on the type of MOUD prescribed) provided transportation to pick up their induction prescription (for buprenorphine or naltrexone) or attend their intake appointment (for methadone). We aim to recruit a total of 273 participants over two years to provide enough power to detect a difference in our primary outcome of MOUD treatment linkage. Secondary outcomes include treatment engagement, treatment retention, and non-MOUD opioid use. Data will be collected using structured interviews and saliva drug tests delivered at baseline, three months, and six months. Fixed and mixed effects generalized linear regression analyses and survival analysis will be conducted to compare the probabilities of a successful treatment linkage between the two arms, days retained in treatment, and post-baseline opioid and other drug use.

Discussion: If successful, STAMINA's telemedicine approach will significantly reduce the amount of time between SSP clients' initial indication of interest in the medication and treatment initiation. Facilitating this process will likely lead to stronger additional treatment- and recovery-oriented outcomes. This study is also timely given the need for more rigorous testing of telemedicine interventions in light of temporary regulatory changes that have occurred during the COVID-19 pandemic.

Trial registration: ClinicalTrials.gov (Clinical Trials ID: NCT04575324 and Protocol Number: 1138-0420). Registered 29 September 2020. The study protocol is also registered on the Open Science Framework (DOI 10.17605/OSF.IO/4853 M).

Keywords: Medication assisted treatment; Medication for opioid use disorder; Substance use disorder; Syringe exchange; Telehealth.

Conflict of interest statement

The authors have no competing interests to declare.

References

    1. Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019;71:183–188. doi: 10.1016/j.drugpo.2019.01.010.
    1. Renner JA, Crawford MB. Medication for the treatment of opioid use disorder. In: Kelly JF, Wakeman SE, editors. Treating opioid addiction. New York: Springer; 2019. pp. 89–107.
    1. Fullerton CA, Kim M, Thomas CP, Lyman DR, Montejano LB, Dougherty RH, Daniels AS, Ghose SS, Delphin-Rittmon ME. Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv. 2014;65(2):146–157. doi: 10.1176/appi.ps.201300235.
    1. Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2028;113(7):1188–1209.
    1. Thomas CP, Fullerton CA, Kim M, Montejano L, Lyman DR, Dougherty RH, Daniels AS, Ghose SS, Delphin-Rittmon ME. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv. 2014;65(2):158–170. doi: 10.1176/appi.ps.201300256.
    1. Treloar C, Rance J, Yates K, Mao L. Trust and people who inject drugs: the perspectives of clients and staff of needle syringe programs. Int J Drug Policy. 2016;27:138–145. doi: 10.1016/j.drugpo.2015.08.018.
    1. Scott CK, Dennis ML, Grella CE, Nicholson L, Sumpter J, Kurz R, et al. Findings from the recovery initiation and management after overdose (RIMO) pilot study experiment. J Subst Abus Treat. 2019;108:65–74. doi: 10.1016/j.jsat.2019.08.004.
    1. Watson DP, Brucker K, McGuire A, Snow-Hill NL, Xu H, Cohen A, et al. Replication of an emergency department-based recovery coaching intervention and pilot testing of pragmatic trial protocols within the context of Indiana’s opioid state targeted response plan. J Subst Abus Treat. 2019;108:88–94. doi: 10.1016/j.jsat.2019.06.002.
    1. Samuels EA, Bernstein SL, Marshall BDL, Krieger M, Baird J, Mello MJ. Peer navigation and take-home naloxone for opioid overdose emergency department patients: preliminary patient outcomes. J Subst Abus Treat. 2018;94:29–34. doi: 10.1016/j.jsat.2018.07.013.
    1. D’Onofrio G, O’Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, Bernstein SL, Fiellin DA. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636–1644. doi: 10.1001/jama.2015.3474.
    1. Hagan H, McGough JP, Thiede H, Hopkins S, Duchin J, Alexander ER. Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. J Subst Abus Treat. 2000;19(3):247–252. doi: 10.1016/S0740-5472(00)00104-5.
    1. Allen ST, Grieb SM, O’Rourke A, Yoder R, Planchet E, White RH, et al. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs. Harm Reduct J. 2019;16:1–10. doi: 10.1186/s12954-019-0305-7.
    1. Treloar C, Newland J, Maher L. A qualitative study trialling the acceptability of new hepatitis C prevention messages for people who inject drugs: symbiotic messages, pleasure and conditional interpretations. Harm Reduct J. 2015;12:1–9. doi: 10.1186/1477-7517-11-34.
    1. Macneil J, Pauly B. Needle exchange as a safe haven in an unsafe world. Aust Prof Soc Alcohol Drugs. 2011;30(1):26–32. doi: 10.1111/j.1465-3362.2010.00188.x.
    1. Cesnales NI, Witt M, Miles BK. Syringe quantity limitations: syringe exchange program participant health behavior and satisfaction. J Soc Work Pract Addict. 2019;19(4):400–413. doi: 10.1080/1533256X.2019.1659066.
    1. Ashford RD, Curtis B, Brown AM. Peer-delivered harm reduction and recovery support services: initial evaluation from a hybrid recovery community drop-in center and syringe exchange program. Harm Reduct J. 2018;15(1):1–9.
    1. Fernandes RM, Cary M, Duarte G, Jesus G, Alarcão J, Torre C, et al. Effectiveness of needle and syringe programmes in people who inject drugs - an overview of systematic reviews. BMC Public Health. 2017;17:1–15. doi: 10.1186/s12889-017-4210-2.
    1. Behrends CN, Li C-S, Gibson DR. Decreased odds of injection risk behavior associated with direct versus indirect use of syringe exchange: evidence from two California cities. Subst Use Misuse. 2017;52:1151–1153. doi: 10.1080/10826084.2017.1299182.
    1. Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, Maher L, Palmateer N, Taylor A, Bruneau J, Hickman M. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane review and meta-analysis. Addiction. 2018;113(3):545–563. doi: 10.1111/add.14012.
    1. Azores-Gococo NM, Fridberg DJ. Harm-reduction strategies for injection drug use. Psychiatr Ann. 2017;47(1):45–48. doi: 10.3928/00485713-20161208-01.
    1. Bramson H, Des Jarlais DC, Arasteh K, Nugent A, Guardino V, Feelemyer J, Hodel D. State laws, syringe exchange, and HIV among persons who inject drugs in the United States: history and effectiveness. J Public Health Policy. 2015;36(2):212–230. doi: 10.1057/jphp.2014.54.
    1. Kidorf M, King VL, Pierce J, Kolodner K, Brooner RK. Benefits of concurrent syringe exchange and substance abuse treatment participation. J Subst Abus Treat. 2011;40(3):265–271. doi: 10.1016/j.jsat.2010.11.011.
    1. Kidorf M, King VL. Expanding the public health benefits of syringe exchange programs. Can J Psychiatry Rev Can Psychiatr. 2008;53(8):487–495. doi: 10.1177/070674370805300803.
    1. Heimer R. Can syringe exchange serve as a conduit to substance abuse treatment? J Subst Abus Treat. 1998;15(3):183–191. doi: 10.1016/S0740-5472(97)00220-1.
    1. Fox AD, Sohler NL, Frost T, Lopez C, Cunningham CO. Development and evaluation of a community-based buprenorphine treatment intervention. Harm Reduct J. 2017;14. 10.1186/s12954-017-0149-y.
    1. Bråbäck M, Nilsson S, Isendahl P, Troberg K, Brådvik L, Håkansson A. Malmö treatment referral and intervention study (MATRIS)-effective referral from syringe exchange to treatment for heroin dependence: a pilot randomized controlled trial. Addiction. 2016;111(5):866–873. doi: 10.1111/add.13249.
    1. Henderson LA, Vlahov D, Celentano DD, Strathdee SA. Readiness for cessation of drug use among recent attenders and nonattenders of a needle exchange program. J Acquir Immune Defic Syndr 1999. 2003;32:229–237. doi: 10.1097/00126334-200302010-00017.
    1. Kidorf M, King VL, Neufeld K, Peirce J, Kolodner K, Brooner RK. Improving substance abuse treatment enrollment in community syringe exchangers. Addiction. 2009;104(5):786–795. doi: 10.1111/j.1360-0443.2009.02560.x.
    1. Kidorf M, Disney E, King V, Kolodner K, Beilenson P, Brooner RK. Challenges in motivating treatment enrollment in community syringe exchange participants. J Urban Health. 2005;82(3):456–467. doi: 10.1093/jurban/jti091.
    1. Kidorf M, King VL, Gandotra N, Kolodner K, Brooner RK. Improving treatment enrollment and re-enrollment rates of syringe exchangers: 12-month outcomes. Drug Alcohol Depend. 2012;124(1-2):162–166. doi: 10.1016/j.drugalcdep.2011.12.008.
    1. Kuo I, Brady J, Butler C, Schwartz R, Brooner R, Vlahov D, Strathdee SA. Feasibility of referring drug users from a needle exchange program into an addiction treatment program: experience with a mobile treatment van and LAAM maintenance. J Subst Abus Treat. 2003;24(1):67–74. doi: 10.1016/S0740-5472(02)00343-4.
    1. Lloyd JJ, Ricketts EP, Strathdee SA, Cornelius LJ, Bishai D, Huettner S, Havens JR, Latkin C. Social contextual factors associated with entry into opiate agonist treatment among injection drug users. Am J Drug Alcohol Abuse. 2005;31(4):555–570. doi: 10.1081/ADA-200068114.
    1. Riley ED, Safaeian M, Strathdee SA, Brooner RK, Beilenson P, Vlahov D. Drug user treatment referrals and entry among participants of a needle exchange program. Subst Use Misuse. 2002;37(14):1869–1886. doi: 10.1081/JA-120014088.
    1. Strathdee SA, Ricketts EP, Huettner S, Cornelius L, Bishai D, Havens JR, Beilenson P, Rapp C, Lloyd JJ, Latkin CA. Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: results from a community-based behavioral intervention trial. Drug Alcohol Depend. 2006;83(3):225–232. doi: 10.1016/j.drugalcdep.2005.11.015.
    1. Havens JR, Lofwall MR, Frost SDW, Oser CB, Leukefeld CG, Crosby RA. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health. 2013;103(1):e44–e52. doi: 10.2105/AJPH.2012.300874.
    1. Havens JR, Latkin CA, Pu M, Cornelius LJ, Bishai D, Huettner S, Rapp C, Ricketts EP, Lloyd JJ, Strathdee SA. Predictors of opiate agonist treatment retention among injection drug users referred from a needle exchange program. J Subst Abus Treat. 2009;36(3):306–312. doi: 10.1016/j.jsat.2008.07.002.
    1. Kidorf M, Brooner RK, Leoutsakos J-M, Peirce J. Treatment initiation strategies for syringe exchange referrals to methadone maintenance: a randomized clinical trial. m. 2018;187:343–350. doi: 10.1016/j.drugalcdep.2018.03.009.
    1. Dennis ML, Ingram PW, Burks ME, Rachal JV. Effectiveness of streamlined admissions to methadone treatment: a simplified time-series analysis. J Psychoactive Drugs. 1994;26(2):207–216. doi: 10.1080/02791072.1994.10472268.
    1. Maddux JF, Desmond DP, Esquivel M. Rapid admission and retention on methadone. Am J Drug Alcohol Abuse. 1995;21(4):533–547. doi: 10.3109/00952999509002714.
    1. Winograd RP, Wood CA, Stringfellow EJ, Presnall N, Duello A, Horn P, et al. Implementation and evaluation of Missouri’s medication first treatment approach for opioid use disorder in publicly-funded substance use treatment programs. J Subst Abus Treat. 2019;108:55–64. doi: 10.1016/j.jsat.2019.06.015.
    1. Fox AD. Onsite buprenorphine treatment at syringe exchange programs. . Accessed on October 23, 2020.
    1. Molfenter T, Boyle M, Holloway D, Zwick J. Trends in telemedicine use in addiction treatment. Addict Sci Clin Pract. 2015;10(1):14. doi: 10.1186/s13722-015-0035-4.
    1. Huskamp HA, Busch AB, Souza J, Uscher-Pines L, Rose S, Wilcock A, Landon BE, Mehrotra A. How is telemedicine being used in opioid and other substance use disorder treatment? Health Aff. 2018;37(12):1940–1947. doi: 10.1377/hlthaff.2018.05134.
    1. Lin L (Allison) Casteel D, Shigekawa E, Weyrich MS, Roby DH, SB MM. Telemedicine-delivered treatment interventions for substance use disorders: a systematic review. J Subst Abuse Treat. 2019;101:38–49. doi: 10.1016/j.jsat.2019.03.007.
    1. Harris M, Johnson S, Mackin S, Saitz R, Walley AY, Taylor JL. Low barrier tele-buprenorphine in the time of COVID-19: a case report. J Addict Med. 2020;14(4):e136–e138.
    1. U.S. Department of Justice, Drug Enforcement Administration. COVID_19 Information Page: telemedicine. . Accessed 25 Jun 2020.
    1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington VA: Author. 2013.
    1. Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS) J Psychoactive Drugs. 2003;35(2):253–259. doi: 10.1080/02791072.2003.10400007.
    1. Kessler RC, Ustün TB. The world mental health (WMH) survey initiative version of the World Health Organization (WHO) composite international diagnostic interview (CIDI) Int J Methods Psychiatr Res. 2004;13(2):93–121. doi: 10.1002/mpr.168.
    1. Kessler RC, Green JG, Gruber MJ, Sampson NA, Bromet E, Cuitan M, Furukawa TA, Gureje O, Hinkov H, Hu CY, Lara C, Lee S, Mneimneh Z, Myer L, Oakley-Browne M, Posada-Villa J, Sagar R, Viana MC, Zaslavsky AM. Screening for serious mental illness in the general population with the K6 screening scale: results from the WHO world mental health (WMH) survey initiative. Int J Methods Psychiatr Res. 2010;19(Suppl 1):4–22. doi: 10.1002/mpr.310.
    1. National Quality Forum . Opioids and opioid use disorder: An environmental scan of quality measures. Washington DC: Author; 2019.
    1. The US Substance Abuse and Mental Health Services Administration . 2018 National Survey on drug use and health: methodological summary and definitions. Washington DC: Author; 2019.
    1. US Centers for Disease Control and Prevention . Measuring Healthy Days. Atlanta: Author; 2000.
    1. Scott CK. A replicable model for achieving over 90% follow-up rates in longitudinal studies of substance abusers. Drug Alcohol Depend. 2004;74(1):21–36. doi: 10.1016/j.drugalcdep.2003.11.007.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010.
    1. Allison P. Why maximum likelihood is better than multiple imputation . Accessed 23 Oct 2020.
    1. Allison P. maximum likelihood is better than multiple imputation: part II . Accessed 23 Oct 2020.
    1. Allison P. Listwise deletion: it’s not evil . Accessed 23 Oct 2020.
    1. Alexander GC, Stoller KB, Haffajee RL, Saloner B. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. Ann Intern Med. 2020;173(1):57–8.
    1. Volkow ND. Collision of the COVID-19 and addiction epidemics. Ann Intern Med. 2020;173(1):61–2.
    1. Creswell JW, Plano Clark VL. Designing and conducting mixed methods research. Thousand Oaks: Sage; 2011.
    1. Williams CT, Ouellet LJ. Misdirected opposition: evidence opposing “not in my back yard” arguments against syringe exchange programmes. Int J Drug Policy. 2010;21(5):437–439. doi: 10.1016/j.drugpo.2010.02.003.
    1. Strathdee SA, Vlahov D. The effectiveness of needle exchange programs: a review of the science and policy. AIDScience. 2001;1:32.
    1. Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, Grebely J, Dumchev KV, Griffiths P, Hines L, Cunningham EB, Mattick RP, Lynskey M, Marsden J, Strang J, Degenhardt L. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5(12):e1208–e1220. doi: 10.1016/S2214-109X(17)30373-X.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться